Literature DB >> 339418

The Duffy blood group and malaria prevalence in Gambian West Africans.

S G Welch, I A McGregor, K Williams.   

Abstract

Erythrocytes from 1,168 donors, comprising almost the entire populations of two rural Gambian villages, have been tested for Duffy blood group antigens using antisera to both Fya and Fyb. All tests were negative. Blood film examination of the same samples showed complete absence of Plasmodium vivax parasitaemia, but infections with P. falciparum,P. malariae and P. ovale were observed. The findings are consistent with the view that the Duffy-negative phenotype, FyFy, constitutes the basis of innate resistance towards infection with P. vivax but not towards infection with the other plasmodial species.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 339418     DOI: 10.1016/0035-9203(77)90102-x

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  18 in total

1.  Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies.

Authors:  Francis B Ntumngia; Jesse Schloegel; Samantha J Barnes; Amy M McHenry; Sanjay Singh; Christopher L King; John H Adams
Journal:  Infect Immun       Date:  2012-01-03       Impact factor: 3.441

2.  The association between a Darc gene polymorphism and clinical outcomes in African American patients with acute lung injury.

Authors:  Kirsten Neudoerffer Kangelaris; Anil Sapru; Carolyn S Calfee; Kathleen D Liu; Ludmila Pawlikowska; John S Witte; Eric Vittinghoff; Hanjing Zhuo; Andrew D Auerbach; Elad Ziv; Michael A Matthay
Journal:  Chest       Date:  2011-12-29       Impact factor: 9.410

3.  Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein.

Authors:  Francis B Ntumngia; John H Adams
Journal:  Clin Vaccine Immunol       Date:  2011-11-23

4.  Isoelectric focusing of human red cell phosphoglucomutase: the distribution of variant phenotypes in a village population from the Gambia, West Africa.

Authors:  S G Welch; C A Swindlehurst; I A McGregor; K Williams
Journal:  Hum Genet       Date:  1978-09-19       Impact factor: 4.132

5.  The international limits and population at risk of Plasmodium vivax transmission in 2009.

Authors:  Carlos A Guerra; Rosalind E Howes; Anand P Patil; Peter W Gething; Thomas P Van Boeckel; William H Temperley; Caroline W Kabaria; Andrew J Tatem; Bui H Manh; Iqbal R F Elyazar; J Kevin Baird; Robert W Snow; Simon I Hay
Journal:  PLoS Negl Trop Dis       Date:  2010-08-03

6.  Duffy Blood Group System and the malaria adaptation process in humans.

Authors:  Gledson Barbosa de Carvalho; Glauber Barbosa de Carvalho
Journal:  Rev Bras Hematol Hemoter       Date:  2011

7.  Genetic variability and natural selection at the ligand domain of the Duffy binding protein in Brazilian Plasmodium vivax populations.

Authors:  Taís N Sousa; Eduardo M Tarazona-Santos; Daniel J Wilson; Ana P Madureira; Paula R K Falcão; Cor J F Fontes; Luiz H S Gil; Marcelo U Ferreira; Luzia H Carvalho; Cristiana F A Brito
Journal:  Malar J       Date:  2010-11-22       Impact factor: 2.979

8.  Worldwide genetic variability of the Duffy binding protein: insights into Plasmodium vivax vaccine development.

Authors:  Taís Nóbrega de Sousa; Luzia Helena Carvalho; Cristiana Ferreira Alves de Brito
Journal:  PLoS One       Date:  2011-08-02       Impact factor: 3.240

9.  High frequency of the erythroid silent Duffy antigen genotype and lack of Plasmodium vivax infections in Haiti.

Authors:  Thomas A Weppelmann; Tamar E Carter; Zhongsheng Chen; Michael E von Fricken; Yves S Victor; Alexander Existe; Bernard A Okech
Journal:  Malar J       Date:  2013-01-24       Impact factor: 2.979

10.  Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein.

Authors:  Brian T Grimberg; Rachanee Udomsangpetch; Jia Xainli; Amy McHenry; Tasanee Panichakul; Jetsumon Sattabongkot; Liwang Cui; Moses Bockarie; Chetan Chitnis; John Adams; Peter A Zimmerman; Christopher L King
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.